Advanced
  Home Compare Reports

Comparison with Similar Reports

Liquid Biopsy Market by Product (Assay Kits, Instruments, Service), Circulating Biomarkers (CTC, ctDNA), Technology (NGS, PCR), Application (Cancer (L...

Publisher:        MarketsandMarkets

# of Pages:        225

Rating: 

1 User License $4,950

Publication Date:  November, 2021

Price:       $4,950 / User License




1 INTRODUCTION 29
1.1 OBJECTIVES OF THE STUDY 29
1.2 MARKET DEFINITION 29
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 30
1.2.2 MARKETS COVERED 31
FIGURE 1 LIQUID BIOPSY MARKET SEGMENTATION 31
1.2.3 YEARS CONSIDERED FOR THE STUDY 32
1.3 CURRENCY 32
1.4 LIMITATIONS 32
1.5 STAKEHOLDERS 33
1.6 SUMMARY OF CHANGES 33
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
2.2 RESEARCH APPROACH 35
FIGURE 2 LIQUID BIOPSY MARKET: RESEARCH DESIGN 35
2.2.1 SECONDARY DATA 36
2.2.1.1 Key data from secondary sources 36
2.2.2 PRIMARY DATA 37
2.2.2.1 Primary sources 37
2.2.2.2 Key data from primary sources 38
2.2.2.3 Key industry insights 39
2.2.2.4 Breakdown of primary interviews 39
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (LIQUID BIOPSY MARKET) 39
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 40
2.3 MARKET SIZE ESTIMATION 40
2.3.1 BOTTOM-UP APPROACH 41
2.3.1.1 Approach 1: Company revenue estimation approach 41
FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 41
2.3.1.2 Approach 2: Presentations of companies and primary interviews 41
2.3.1.3 Growth forecast (2021-2026) 42
2.3.1.4 CAGR projections 42
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 42
2.3.2 TOP-DOWN APPROACH 42
FIGURE 7 LIQUID BIOPSY MARKET: TOP-DOWN APPROACH 43
 
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 44
FIGURE 8 DATA TRIANGULATION METHODOLOGY 44
2.5 MARKET SHARE 45
2.6 ASSUMPTIONS FOR THE STUDY 45
2.7 LIMITATIONS 46
2.8 RISK ASSESSMENT 46
2.8.1 RISK ASSESSMENT: LIQUID BIOPSY MARKET 46
2.9 GROWTH RATE ASSUMPTIONS 47
2.10 COVID-19 HEALTH ASSESSMENT 47
2.11 COVID-19 ECONOMIC ASSESSMENT 47
2.12 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 47
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY 48
FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 49
2.13 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE LIQUID BIOPSY MARKET 50
3 EXECUTIVE SUMMARY 51
FIGURE 11 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2021 VS. 2026 (USD MILLION) 51
FIGURE 12 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2021 VS. 2026 (USD MILLION) 52
FIGURE 13 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION) 52
FIGURE 14 LIQUID BIOPSY MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION) 53
FIGURE 15 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2021 VS. 2026 (USD MILLION) 53
FIGURE 16 LIQUID BIOPSY MARKET, BY END USER, 2021 VS. 2026 (USD MILLION) 54
FIGURE 17 LIQUID BIOPSY MARKET, BY REGION, 2021 VS. 2026 (USD MILLION) 55
4 PREMIUM INSIGHTS 56
4.1 LIQUID BIOPSY MARKET OVERVIEW 56
FIGURE 18 THE RISING INCIDENCE OF CANCER IS DRIVING THE GROWTH OF THE LIQUID BIOPSY MARKET 56
4.2 LIQUID BIOPSY MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026 57
FIGURE 19 THE ASSAY KITS SEGMENT WILL CONTINUE TO DOMINATE
THE MARKET IN 2026 57
4.3 LIQUID BIOPSY MARKET SHARE, BY CIRCULATING BIOMARKERS, 2021 VS. 2026 57
FIGURE 20 THE CIRCULATING TUMOR CELLS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026 57
4.4 LIQUID BIOPSY MARKET SHARE, BY TECHNOLOGY, 2021 VS. 2026 58
FIGURE 21 MULTI-GENE PARALLEL ANALYSIS USING NGS SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026 58
4.5 LIQUID BIOPSY MARKET SHARE, BY APPLICATION, 2021 VS. 2026 58
FIGURE 22 CANCER APPLICATIONS SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026 58
4.6 LIQUID BIOPSY MARKET SHARE, BY CLINICAL APPLICATION, 2021 VS. 2026 59
FIGURE 23 THERAPY SELECTION SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 59
4.7 LIQUID BIOPSY MARKET SHARE, BY END USER, 2021 VS. 2026 59
FIGURE 24 REFERENCE LABORATORIES SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026 59
4.8 LIQUID BIOPSY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 60
FIGURE 25 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE LIQUID BIOPSY MARKET DURING THE FORECAST PERIOD 60
5 MARKET OVERVIEW 61
5.1 INTRODUCTION 61
5.2 MARKET DYNAMICS 61
FIGURE 26 LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 61
5.2.1 DRIVERS 62
5.2.1.1 Rising incidence and prevalence of cancer 62
TABLE 1 NUMBER OF PREVALENT CANCER CASES WORLDWIDE IN 2020,
BY TYPE OF CANCER 62
5.2.1.2 Cancer awareness initiatives undertaken by global health organizations 63
5.2.1.3 Increasing preference for noninvasive treatment procedures 63
5.2.2 RESTRAINTS 64
5.2.2.1 The lower sensitivity of certain liquid biopsies 64
5.2.3 OPPORTUNITIES 65
5.2.3.1 The growing significance of companion diagnostics 65
5.2.3.2 Growth opportunities in emerging countries 65
5.2.4 CHALLENGES 66
5.2.4.1 Unclear reimbursement scenario 66
5.3 IMPACT OF COVID-19 ON THE LIQUID BIOPSY MARKET 66
5.4 REALISTIC, PESSIMISTIC, AND OPTIMISTIC SCENARIOS 67
5.4.1 LIQUID BIOPSY MARKET 67
FIGURE 27 REALISTIC SCENARIO 67
FIGURE 28 PESSIMISTIC SCENARIO 68
FIGURE 29 OPTIMISTIC SCENARIO 68
5.5 PRICING ANALYSIS 69
TABLE 2 PRICE OF LIQUID BIOPSY PRODUCTS (2021) 69
5.6 PATENT ANALYSIS 70
5.6.1 PATENT ANALYSIS OF CIRCULATING BIOMARKERS 70
5.7 VALUE CHAIN ANALYSIS 71
FIGURE 30 MAJOR VALUE IS ADDED DURING THE MANUFACTURING & ASSEMBLY PHASE 71
FIGURE 31 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES 72
5.8 ECOSYSTEM ANALYSIS OF THE LIQUID BIOPSY MARKET 73
FIGURE 32 LIQUID BIOPSY MARKET: ECOSYSTEM ANALYSIS 73
5.9 PORTER’S FIVE FORCES ANALYSIS 73
TABLE 3 LIQUID BIOPSY MARKET: PORTER’S FIVE FORCES ANALYSIS 73
5.9.1 THREAT OF NEW ENTRANTS 74
5.9.2 THREAT OF SUBSTITUTES 74
5.9.3 BARGAINING POWER OF BUYERS 74
5.9.4 BARGAINING POWER OF SUPPLIERS 74
5.9.5 DEGREE OF COMPETITION 74
5.10 REGULATORY LANDSCAPE 74
5.10.1 NORTH AMERICA 74
5.10.1.1 US 74
5.10.1.2 Canada 75
5.10.2 EUROPE 75
5.10.3 ASIA PACIFIC 75
5.10.3.1 China 75
5.10.3.2 Japan 75
5.10.4 LATIN AMERICA 75
5.10.4.1 Brazil 76
5.10.4.2 Mexico 76
5.10.5 MIDDLE EAST 76
5.10.6 AFRICA 76
5.11 TECHNOLOGY ANALYSIS 77
5.12 PESTLE ANALYSIS 78
5.13 TRADE ANALYSIS 79
5.13.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 79
5.13.1.1 Import data for diagnostic and laboratory reagents, by country, 2016─2020 (USD Million) 79
5.13.1.2 Import data for diagnostic and laboratory reagents, by country, 2016─2020 (Tons) 79
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES 79
5.14.1 REVENUE SHIFT & REVENUE POCKETS FOR LIQUID BIOPSY PRODUCT MANUFACTURERS 79
5.14.2 REVENUE SHIFT FOR THE LIQUID BIOPSY MARKET 80
6 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE 81
6.1 INTRODUCTION 82
TABLE 4 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 82
6.2 ASSAY KITS 82
6.2.1 REPEATED REQUIREMENT PURCHASES OF ASSAY KITS TO DRIVE THE GROWTH OF THIS SEGMENT 82
TABLE 5 KEY PRODUCTS IN THE ASSAY KITS MARKET 83
TABLE 6 LIQUID BIOPSY MARKET FOR ASSAY KITS, BY REGION,
2019–2026 (USD MILLION) 83
 
6.3 INSTRUMENTS 84
6.3.1 LATEST ADVANCEMENTS IN PCR TECHNOLOGIES TO ENSURE MARKET GROWTH OF THIS SEGMENT 84
TABLE 7 KEY PRODUCTS IN THE INSTRUMENTS MARKET 85
TABLE 8 LIQUID BIOPSY MARKET FOR INSTRUMENTS, BY REGION,
2019–2026 (USD MILLION) 85
6.4 SERVICES 85
6.4.1 INCREASING NUMBER OF LIQUID BIOPSY-BASED SERVICE DEVELOPMENTS TO SUPPORT THE MARKET GROWTH 85
TABLE 9 LIQUID BIOPSY MARKET FOR SERVICES, BY REGION,
2019–2026 (USD MILLION) 86
7 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS 87
7.1 INTRODUCTION 88
7.1.1 PRIMARY NOTES 88
7.1.1.1 Key industry insights 88
TABLE 10 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 88
7.2 CIRCULATING TUMOR CELLS (CTC) 89
7.2.1 BENEFITS OF EASY COLLECTION AND PERSISTENT ASSESSMENT & ANALYSIS OF THE OVERALL TUMOR BURDEN TO DRIVE THE GROWTH OF THIS SEGMENT 89
TABLE 11 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY REGION, 2019–2026 (USD MILLION) 89
7.3 CIRCULATING TUMOR DNA (CTDNA) 90
7.3.1 CTDNA ANALYSIS CAN SIGNIFICANTLY IMPROVE TUMOR DIAGNOSIS, THUS LEADING TO EARLY-STAGE DETECTION OF CANCER 90
TABLE 12 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY REGION,
2019–2026 (USD MILLION) 90
7.4 CELL-FREE DNA (CFDNA) 91
7.4.1 APPLICATION OF CFDNA IN PRENATAL SCREENING IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT 91
TABLE 13 LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY REGION,
2019–2026 (USD MILLION) 91
7.5 EXTRACELLULAR VESICLES (EVS) 91
7.5.1 EVS ARE STABLE IN BLOOD CIRCULATION OVER OTHER ANALYTES, THUS ENSURING THE GROWTH OF THIS SEGMENT 91
TABLE 14 LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY REGION,
2019–2026 (USD MILLION) 92
7.6 OTHER CIRCULATING BIOMARKERS 92
TABLE 15 LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY REGION, 2019–2026 (USD MILLION) 93
 
8 LIQUID BIOPSY MARKET, BY TECHNOLOGY 94
8.1 INTRODUCTION 95
8.1.1 PRIMARY NOTES 95
8.1.1.1 Key industry insights 95
TABLE 16 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 95
8.2 MULTI-GENE PARALLEL ANALYSIS USING NGS 95
8.2.1 HIGH SENSITIVITY AND ECONOMIC BENEFITS TO DRIVE
THE GROWTH OF THIS SEGMENT 95
TABLE 17 LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, 2019–2026 (USD MILLION) 96
8.3 SINGLE-GENE ANALYSIS USING PCR MICROARRAYS 96
8.3.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE THE GROWTH OF THIS SEGMENT 96
TABLE 18 LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, 2019–2026 (USD MILLION) 96
9 LIQUID BIOPSY MARKET, BY APPLICATION 97
9.1 INTRODUCTION 98
TABLE 19 LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 98
9.2 CANCER APPLICATIONS 98
TABLE 20 CANCER INCIDENCE, BY REGION, 2020 VS. 2040 (MILLION) 99
TABLE 21 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY REGION,
2019–2026 (USD MILLION) 99
TABLE 22 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE,
2019–2026 (USD MILLION) 100
9.2.1 LUNG CANCER 100
9.2.1.1 Increasing prevalence of lung cancer to propel the market growth 100
TABLE 23 LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040 101
TABLE 24 LIQUID BIOPSY MARKET FOR LUNG CANCER, BY REGION,
2019–2026 (USD MILLION) 101
9.2.2 BREAST CANCER 102
9.2.2.1 Increasing government funding for breast cancer research is expected to drive the market growth 102
TABLE 25 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040 103
TABLE 26 LIQUID BIOPSY MARKET FOR BREAST CANCER, BY REGION,
2019–2026 (USD MILLION) 103
9.2.3 COLORECTAL CANCER 103
9.2.3.1 Increasing prevalence of colorectal cancer to propel the market growth 103
TABLE 27 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040 104
TABLE 28 LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY REGION,
2019–2026 (USD MILLION) 104
9.2.4 PROSTATE CANCER 105
9.2.4.1 Growing number of prostate cancer patients to drive the growth of this market 105
TABLE 29 PROSTATE CANCER INCIDENCE, BY REGION, 2020 VS. 2040 105
TABLE 30 LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY REGION,
2019–2026 (USD MILLION) 106
9.2.5 MELANOMA 106
9.2.5.1 Increasing need for the early diagnosis of genetically mutated tumors to drive market growth 106
TABLE 31 MELANOMA INCIDENCE, BY REGION, 2020 VS. 2040 107
TABLE 32 LIQUID BIOPSY MARKET FOR MELANOMA, BY REGION,
2019–2026 (USD MILLION) 107
9.2.6 OTHER CANCERS 107
TABLE 33 GLOBAL CANCER INCIDENCE, 2020 108
TABLE 34 LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY REGION,
2019–2026 (USD MILLION) 108
9.3 NON-CANCER APPLICATIONS 108
9.3.1 APPLICATIONS OF LIQUID BIOPSY FOR NIPT AND ORGAN TRANSPLANTATION DIAGNOSIS DRIVES THE GROWTH OF THIS SEGMENT 108
TABLE 35 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY REGION, 2019–2026 (USD MILLION) 109
10 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION 110
10.1 INTRODUCTION 111
TABLE 36 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 111
10.2 THERAPY SELECTION 111
10.2.1 INCREASING PREFERENCE DUE TO NONINVASIVENESS OF LIQUID BIOPSY TESTS TO DRIVE THE GROWTH OF THIS SEGMENT 111
TABLE 37 LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY REGION,
2019–2026 (USD MILLION) 112
10.3 TREATMENT MONITORING 112
10.3.1 LIQUID BIOPSY FOR TREATMENT MONITORING QUANTITATIVELY CALCULATES THE CONCENTRATION OF CANCER-RELATED MUTATIONS 112
TABLE 38 LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY REGION,
2019–2026 (USD MILLION) 113
10.4 RECURRENCE MONITORING 113
10.4.1 THE ABILITY TO DETECT CANCER MUTATION THROUGH CTDNA IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT 113
TABLE 39 LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY REGION, 2019–2026 (USD MILLION) 114
10.5 EARLY CANCER SCREENING 114
10.5.1 POTENTIAL OF LIQUID BIOPSY IN THE DETECTION OF CANCER AT EARLY STAGES TO DRIVE MARKET GROWTH 114
TABLE 40 LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY REGION, 2019–2026 (USD MILLION) 115
 
11 LIQUID BIOPSY MARKET, BY END USER 116
11.1 INTRODUCTION 117
TABLE 41 LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION) 117
11.2 REFERENCE LABORATORIES 117
11.2.1 INCREASING OUTSOURCING OF LIQUID BIOPSY TESTS TO REFERENCE LABORATORIES DRIVES THE GROWTH OF THIS SEGMENT 117
TABLE 42 LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY REGION, 2019–2026 (USD MILLION) 118
11.3 HOSPITALS AND PHYSICIAN LABORATORIES 118
11.3.1 THE INCREASING NUMBER OF HOSPITALS WORLDWIDE IS A MAJOR FACTOR DRIVING THE GROWTH OF THIS SEGMENT 118
TABLE 43 LIQUID BIOPSY MARKET FOR HOSPITALS AND PHYSICIAN LABORATORIES,
BY REGION, 2019–2026 (USD MILLION) 119
11.4 ACADEMIC & RESEARCH CENTERS 119
11.4.1 GROWING FOCUS OF RESEARCH IN THE DEVELOPMENT OF INNOVATIVE LIQUID BIOPSY TESTS TO DRIVE THE GROWTH OF THIS END-USER SEGMENT 119
TABLE 44 LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY REGION, 2019–2026 (USD MILLION) 120
11.5 OTHER END USERS 120
TABLE 45 LIQUID BIOPSY MARKET FOR OTHER END USERS, BY REGION,
2019–2026 (USD MILLION) 120
12 LIQUID BIOPSY MARKET, BY REGION 121
12.1 INTRODUCTION 122
TABLE 46 LIQUID BIOPSY MARKET, BY REGION, 2019–2026 (USD MILLION) 122
12.2 NORTH AMERICA 122
TABLE 47 NUMBER OF NEW CANCER CASES IN NORTH AMERICA IN 2020,
BY TYPE OF CANCER 123
FIGURE 33 NORTH AMERICA: LIQUID BIOPSY MARKET SNAPSHOT 124
TABLE 48 NORTH AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 124
TABLE 49 NORTH AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 125
TABLE 50 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS, 2019–2026 (USD MILLION) 125
TABLE 51 NORTH AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 125
TABLE 52 NORTH AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 126
TABLE 53 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2019–2026 (USD MILLION) 126
TABLE 54 NORTH AMERICA: LIQUID BIOPSY MARKET, BY END USER,
2019–2026 (USD MILLION) 126
12.2.1 US 127
12.2.1.1 The increasing prevalence of cancer is a key factor expected to drive market growth in the US 127
TABLE 55 US: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 127
TABLE 56 US: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 128
TABLE 57 US: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 128
TABLE 58 US: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 128
TABLE 59 US: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 129
TABLE 60 US: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION) 129
12.2.2 CANADA 129
12.2.2.1 The availability of various cancer screening programs in Canada is expected to drive market growth in Canada 129
TABLE 61 CANADA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 130
TABLE 62 CANADA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 130
TABLE 63 CANADA: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 131
TABLE 64 CANADA: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 131
TABLE 65 CANADA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 131
TABLE 66 CANADA: LIQUID BIOPSY MARKET, BY END USER,
2019–2026 (USD MILLION) 132
12.3 EUROPE 132
TABLE 67 EUROPE: LIQUID BIOPSY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 133
TABLE 68 EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 133
TABLE 69 EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 133
TABLE 70 EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 134
TABLE 71 EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 134
TABLE 72 EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 134
TABLE 73 EUROPE: LIQUID BIOPSY MARKET, BY END USER,
2019–2026 (USD MILLION) 135
12.3.1 GERMANY 135
12.3.1.1 Increasing healthcare expenditure to drive the market growth in Germany 135
TABLE 74 GERMANY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 136
TABLE 75 GERMANY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 136
TABLE 76 GERMANY: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 136
TABLE 77 GERMANY: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 137
TABLE 78 GERMANY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 137
TABLE 79 GERMANY: LIQUID BIOPSY MARKET, BY END USER,
2019–2026 (USD MILLION) 137
12.3.2 UK 138
12.3.2.1 Increasing number of diagnostic laboratories in the UK to propel the market growth 138
TABLE 80 UK: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 138
TABLE 81 UK: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 139
TABLE 82 UK: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 139
TABLE 83 UK: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 139
TABLE 84 UK: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 140
TABLE 85 UK: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION) 140
12.3.3 FRANCE 140
12.3.3.1 Rising R&D expenditure in France to drive the market growth 140
TABLE 86 FRANCE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 141
TABLE 87 FRANCE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 141
TABLE 88 FRANCE: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 141
TABLE 89 FRANCE: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 142
TABLE 90 FRANCE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 142
TABLE 91 FRANCE: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION) 142
12.3.4 REST OF EUROPE 143
TABLE 92 ROE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 143
TABLE 93 ROE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 143
TABLE 94 ROE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 144
TABLE 95 ROE: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 144
TABLE 96 ROE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 144
TABLE 97 ROE: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION) 145
12.4 ASIA PACIFIC 145
FIGURE 34 APAC: LIQUID BIOPSY MARKET SNAPSHOT 146
TABLE 98 APAC: LIQUID BIOPSY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 146
TABLE 99 APAC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 147
TABLE 100 APAC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 147
TABLE 101 APAC: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 147
TABLE 102 APAC: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 148
TABLE 103 APAC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 148
TABLE 104 APAC: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION) 148
12.4.1 CHINA 149
12.4.1.1 Growing public access to advanced healthcare facilities to drive the market growth in China 149
TABLE 105 CHINA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 149
TABLE 106 CHINA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 149
TABLE 107 CHINA: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 150
TABLE 108 CHINA: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 150
TABLE 109 CHINA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 150
TABLE 110 CHINA: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION) 151
12.4.2 JAPAN 151
12.4.2.1 Universal healthcare reimbursement policy to drive the market growth in Japan 151
TABLE 111 JAPAN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 151
TABLE 112 JAPAN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 152
TABLE 113 JAPAN: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 152
TABLE 114 JAPAN: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 152
TABLE 115 JAPAN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 153
TABLE 116 JAPAN: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION) 153
12.4.3 INDIA 153
12.4.3.1 Increasing private & public investments in the country’s healthcare system is expected to drive the market growth 153
TABLE 117 INDIA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 154
TABLE 118 INDIA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 154
TABLE 119 INDIA: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 155
TABLE 120 INDIA: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 155
TABLE 121 INDIA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 155
TABLE 122 INDIA: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION) 156
12.4.4 REST OF ASIA PACIFIC 156
TABLE 123 ROAPAC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 156
TABLE 124 ROAPAC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 157
TABLE 125 ROAPAC: LIQUID BIOPSY MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 157
TABLE 126 ROAPAC: LIQUID BIOPSY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 157
TABLE 127 ROAPAC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 158
TABLE 128 ROAPAC: LIQUID BIOPSY MARKET, BY END USER,
2019–2026 (USD MILLION) 158
12.5 REST OF THE WORLD 158
TABLE 129 ROW: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 159
TABLE 130 ROW: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKERS,
2019–2026 (USD MILLION) 159
TABLE 131 ROW: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 159
TABLE 132 ROW: LIQUID BIOPSY MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 160
TABLE 133 ROW: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2019–2026 (USD MILLION) 160
TABLE 134 ROW: LIQUID BIOPSY MARKET, BY END USER, 2019–2026 (USD MILLION) 160
13 COMPETITIVE LANDSCAPE 161
13.1 OVERVIEW 161
13.2 KEY PLAYER STRATEGIES 161
13.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN
THE LIQUID BIOPSY MARKET 161
TABLE 135 OVERVIEW OF STRATEGIES DEPLOYED BY SOME LIQUID BIOPSY PRODUCT MANUFACTURING COMPANIES 161
13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 163
FIGURE 35 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN
THE LIQUID BIOPSY MARKET 163
13.4 MARKET SHARE ANALYSIS 164
FIGURE 36 LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER (2020) 164
TABLE 136 LIQUID BIOPSY MARKET: DEGREE OF COMPETITION 164
13.5 COMPANY EVALUATION QUADRANT 165
13.5.1 LIST OF EVALUATED VENDORS 165
13.5.2 STARS 165
13.5.3 EMERGING LEADERS 166
13.5.4 PERVASIVE PLAYERS 166
13.5.5 PARTICIPANTS 166
FIGURE 37 LIQUID BIOPSY MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020 166
13.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2020) 167
13.6.1 PROGRESSIVE COMPANIES 167
13.6.2 STARTING BLOCKS 167
13.6.3 RESPONSIVE COMPANIES 167
13.6.4 DYNAMIC COMPANIES 167
FIGURE 38 LIQUID BIOPSY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2020 168
13.7 COMPETITIVE BENCHMARKING 168
FIGURE 39 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN THE LIQUID BIOPSY MARKET 168
TABLE 137 COMPANY PRODUCT TYPE FOOTPRINT 169
TABLE 138 COMPANY GEOGRAPHICAL FOOTPRINT 169
13.8 COMPETITIVE SCENARIO 170
13.8.1 PRODUCT LAUNCHES AND REGULATORY APPROVALS 170
TABLE 139 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS 170
13.8.2 DEALS 171
TABLE 140 KEY DEALS 171
13.8.3 LIQUID BIOPSY: OTHER DEVELOPMENTS 172
TABLE 141 OTHER KEY DEVELOPMENTS 172
14 COMPANY PROFILES 173
14.1 KEY PLAYERS 173
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
14.1.1 QIAGEN N.V. 173
TABLE 142 QIAGEN N.V.: BUSINESS OVERVIEW 173
FIGURE 40 QIAGEN N.V.: COMPANY SNAPSHOT (2020) 174
14.1.2 F. HOFFMANN-LA ROCHE 177
TABLE 143 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW 177
FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020) 178
14.1.3 MYRIAD GENETICS, INC. 180
TABLE 144 MYRIAD GENETICS, INC.: BUSINESS OVERVIEW 180
FIGURE 42 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2020) 181
14.1.4 THERMO FISHER SCIENTIFIC INC. 184
TABLE 145 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 184
FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020) 185
14.1.5 GUARDANT HEALTH, INC. 188
TABLE 146 GUARDANT HEALTH, INC.: BUSINESS OVERVIEW 188
FIGURE 44 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2020) 189
14.1.6 BIO-RAD LABORATORIES 192
TABLE 147 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 192
FIGURE 45 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2020) 193
14.1.7 ILLUMINA, INC. 195
TABLE 148 ILLUMINA, INC.: BUSINESS OVERVIEW 195
FIGURE 46 ILLUMINA: COMPANY SNAPSHOT (2020) 196
14.1.8 EXACT SCIENCES 198
TABLE 149 EXACT SCIENCES: BUSINESS OVERVIEW 198
FIGURE 47 EXACT SCIENCES: COMPANY SNAPSHOT (2020) 199
14.1.9 SYSMEX INOSTICS (SUBSIDIARY OF SYSMEX CORPORATION) 201
TABLE 150 SYSMEX INOSTICS: BUSINESS OVERVIEW 201
FIGURE 48 SYSMEX CORPORATION: COMPANY SNAPSHOT (2020) 201
14.1.10 BIOCEPT, INC. 203
TABLE 151 BIOCEPT, INC.: BUSINESS OVERVIEW 203
FIGURE 49 BIOCEPT, INC.: COMPANY SNAPSHOT (2020) 203
14.1.11 MDX HEALTH 207
TABLE 152 MDX HEALTH: BUSINESS OVERVIEW 207
FIGURE 50 MDX HEALTH: COMPANY SNAPSHOT (2020) 207
14.2 OTHER PLAYERS 209
14.2.1 NEOGENOMICS, INC. 209
14.2.2 ANGLE PLC 211
14.2.3 EPIGENOMICS AG 212
14.2.4 MENARINI-SILICON BIOSYSTEMS 213
14.2.5 VORTEX BIOSCIENCES, INC. 214
14.2.6 EXOSOME DIAGNOSTICS, INC. 215
14.2.7 MEDGENOME INC. 216
14.2.8 AGENA BIOSCIENCE, INC. 217
14.2.9 PERSONAL GENOME DIAGNOSTICS, INC. 219
14.2.10 FREENOME HOLDINGS, INC. 221
14.2.11 STRAND LIFE SCIENCES 222
14.2.12 LUNGLIFE AI, INC. 222
14.2.13 LUCENE HEALTH INC. 223
14.2.14 ANPAC BIO-MEDICAL SCIENCE CO., LTD. 223
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
15 APPENDIX 224
15.1 DISCUSSION GUIDE 224
15.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 228
15.3 AVAILABLE CUSTOMIZATIONS 230
15.4 RELATED REPORTS 230
15.5 AUTHOR DETAILS 231

Lateral Flow Assay Components Market by Type, Application Type (Clinical Testing (Infectious, Cardiac Marker Test) Veterinary, Food Safety), Technique...

Publisher:        MarketsandMarkets

# of Pages:        224

Rating: 

1 User License $4,950

Publication Date:  April, 2022

Price:       $4,950 / User License




1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.2.1 CATEGORY-WISE INCLUSIONS AND EXCLUSIONS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 33
1.3 MARKET SCOPE 34
1.3.1 MARKETS COVERED 34
FIGURE 1 LATERAL FLOW ASSAY COMPONENTS MARKET SEGMENTATION 34
1.3.2 YEARS CONSIDERED FOR THE STUDY 35
1.4 CURRENCY 35
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 35
1.5 STAKEHOLDERS 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH APPROACH 36
FIGURE 2 RESEARCH DESIGN 36
2.1.1 SECONDARY DATA 36
2.1.1.1 Key data from secondary sources 37
2.1.2 PRIMARY DATA 38
2.1.2.1 Primary sources 38
2.1.2.2 Key data from primary sources 39
2.1.2.3 Breakdown of primaries 39
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE):
BY COMPANY TYPE, DESIGNATION, AND REGION 39
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 40
2.2 MARKET SIZE ESTIMATION 40
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021) 41
FIGURE 6 SUPPLY-SIDE ANALYSIS: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 42
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 44
FIGURE 7 DATA TRIANGULATION METHODOLOGY 45
2.4 KEY INDUSTRY INSIGHTS 46
2.5 LIMITATIONS 46
2.5.1 METHODOLOGY-RELATED LIMITATIONS 46
2.6 RISK ASSESSMENT 47
2.7 ASSUMPTIONS FOR THE STUDY 47
 
3 EXECUTIVE SUMMARY 48
FIGURE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2022 VS. 2027 (USD MILLION) 48
FIGURE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2022 VS. 2027 (USD MILLION) 49
FIGURE 10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION) 50
FIGURE 11 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2022 VS. 2027 (USD MILLION) 51
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 52
4 PREMIUM INSIGHTS 53
4.1 LATERAL FLOW ASSAY COMPONENTS MARKET OVERVIEW 53
FIGURE 13 RISING NUMBER OF LOCAL MANUFACTURERS FOR COMPONENTS IS DRIVING THE GROWTH OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 53
4.2 REGIONAL MIX: LATERAL FLOW ASSAY COMPONENTS MARKET 54
FIGURE 14 APAC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 54
4.3 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE AND COUNTRY 55
FIGURE 15 MEMBRANES ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021 55
4.4 LATERAL FLOW ASSAY COMPONENTS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 56
4.5 LATERAL FLOW ASSAY COMPONENTS MARKET: DEVELOPED VS. DEVELOPING COUNTRIES 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS: IMPACT ANALYSIS 57
5.2.1 DRIVERS 58
5.2.1.1 Growing demand for lateral flow assay kits due
to the COVID-19 pandemic 58
5.2.1.2 Growing usage of home-based lateral flow assay devices 58
5.2.1.3 Growing demand for point-of-care testing 58
5.2.1.4 Increasing public-private investments to develop lateral flow assays 59
5.2.2 RESTRAINTS 59
5.2.2.1 Availability of alternative diagnostic technologies 59
5.2.3 OPPORTUNITIES 59
5.2.3.1 Evolving applications of lateral flow assays 59
5.2.4 CHALLENGES 60
5.2.4.1 Requirement of specialized storage and shipping facilities for membranes 60
5.3 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES (YC-YCC) IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
FIGURE 16 YC–YCC SHIFT IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 61
5.5 AVERAGE SELLING PRICE TREND 61
TABLE 2 AVERAGE SELLING PRICE OF LATERAL FLOW ASSAY COMPONENTS,
BY REGION, 2021 (USD) 61
5.6 ECOSYSTEM MARKET MAP 62
FIGURE 17 ECOSYSTEM: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 62
5.7 PATENT ANALYSIS 63
5.7.1 PATENT PUBLICATION TRENDS FOR LATERAL FLOW ASSAYS 63
FIGURE 18 GLOBAL PATENT PUBLICATION TRENDS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2016–2021 64
5.7.2 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 64
FIGURE 19 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR LATERAL FLOW ASSAYS COMPONENTS, 2016–2021 64
5.8 VALUE CHAIN ANALYSIS 65
5.9 REGULATORY LANDSCAPE 66
TABLE 3 REGULATORY STANDARDS/APPROVALS REQUIRED FOR LATERAL FLOW IMMUNOASSAY PRODUCTS, BY COUNTRY/REGION 66
5.9.1 NORTH AMERICA 66
5.9.2 EUROPE 67
5.9.3 ASIA PACIFIC 67
5.9.3.1 India 67
5.9.3.2 China 67
5.9.3.3 Japan 68
5.10 TECHNOLOGY ANALYSIS 69
5.10.1 KEY TECHNOLOGY: LATERAL FLOW ASSAYS 69
5.11 KEY CONFERENCES & EVENTS DURING 2021–2023 69
TABLE 4 LATERAL FLOW ASSAY COMPONENTS MARKET: DETAILED LIST OF CONFERENCES & EVENTS 69
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 70
5.12.1 KEY STAKEHOLDERS IN THE BUYING PROCESS 70
FIGURE 20 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
TABLE 5 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
5.12.2 BUYING CRITERIA 71
FIGURE 21 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
TABLE 6 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
5.13 PORTER’S FIVE FORCES ANALYSIS 72
TABLE 7 LATERAL FLOW ASSAY COMPONENTS MARKET:
PORTER’S FIVE FORCES ANALYSIS 72
5.13.1 THREAT FROM NEW ENTRANTS 72
5.13.2 THREAT FROM SUBSTITUTES 72
5.13.3 BARGAINING POWER OF BUYERS 73
5.13.4 BARGAINING POWER OF SUPPLIERS 73
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 73
6 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE 74
6.1 INTRODUCTION 75
TABLE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 75
6.2 MEMBRANES 75
TABLE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE,
2020–2027 (USD MILLION) 76
TABLE 10 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 76
6.2.1 NITROCELLULOSE MEMBRANES 77
6.2.1.1 Advantages of nitrocellulose membranes such as high protein-binding affinity and compatibility with a wide range of detection methods to drive market growth 77
TABLE 11 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 12 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (1 X 1 M SHEETS), BY REGION, 2020–2027 (IN THOUSANDS) 78
TABLE 13 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (20 MM X 1 M ROLLS), BY REGION, 2020–2027 (IN MILLIONS) 78
6.2.2 OTHER MEMBRANES 78
TABLE 14 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 79
6.3 PADS 80
TABLE 15 EXAMPLES OF DIFFERENT MATERIALS USED IN MANUFACTURING LATERAL FLOW ASSAY PADS 80
TABLE 16 LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 80
TABLE 17 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PADS, BY COUNTRY, 2020–2027 (USD MILLION) 81
6.3.1 SAMPLE PADS 81
6.3.1.1 Ability to promote even and controlled distribution of samples to drive market growth 81
TABLE 18 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SAMPLE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 82
6.3.2 CONJUGATE PADS 82
6.3.2.1 Conjugate pads play an important role in controlling the performance of lateral flow immunoassays 82
TABLE 19 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CONJUGATE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 83
6.3.3 ABSORBENT PADS 84
6.3.3.1 Absorbent pads prevent backflow—a key factor driving market growth 84
TABLE 20 LATERAL FLOW ASSAY COMPONENTS MARKET FOR ABSORBENT PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 84
6.4 OTHER COMPONENTS 84
TABLE 21 OTHER LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 85
7 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION 86
7.1 INTRODUCTION 87
TABLE 22 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 87
7.2 CLINICAL TESTING 87
TABLE 23 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 88
TABLE 24 LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 88
7.2.1 INFECTIOUS DISEASE TESTING 89
7.2.1.1 Rising demand for infectious disease testing in emerging markets to drive market growth 89
TABLE 25 LATERAL FLOW ASSAY COMPONENTS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 89
7.2.2 PREGNANCY & FERTILITY TESTING 90
7.2.2.1 Growing infertility levels due to changing lifestyles—a key factor driving market growth 90
TABLE 26 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PREGNANCY & FERTILITY TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 90
7.2.3 CARDIAC MARKER TESTING 91
7.2.3.1 Rising prevalence of cardiovascular diseases and growing government support to drive growth in this market segment 91
TABLE 27 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CARDIAC MARKER TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 92
7.2.4 CHOLESTEROL TESTING/LIPID PROFILING 92
7.2.4.1 Growing prevalence of obesity and CVD—
a key factor driving market growth 92
TABLE 28 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CHOLESTEROL TESTING/LIPID PROFILING, BY COUNTRY, 2020–2027 (USD MILLION) 93
7.2.5 DRUGS-OF-ABUSE TESTING 93
7.2.5.1 Technological advancements and a growing focus on workplace
drug testing are driving market growth 93
TABLE 29 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUGS-OF-ABUSE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 94
7.2.6 OTHER CLINICAL TESTING APPLICATIONS 94
TABLE 30 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER CLINICAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 95
7.3 VETERINARY DIAGNOSTICS 95
7.3.1 INFECTIOUS DISEASE OUTBREAKS (PARTICULARLY IN LARGE LIVESTOCK ANIMALS) TO DRIVE MARKET GROWTH 95
TABLE 31 LATERAL FLOW ASSAY COMPONENTS MARKET FOR VETERINARY DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 96
7.4 FOOD SAFETY & ENVIRONMENTAL TESTING 96
7.4.1 HIGH SENSITIVITY AND EASE OF USE ARE KEY FACTORS DRIVING THE DEMAND FOR LATERAL FLOW ASSAYS FOR FOOD SAFETY TESTING 96
TABLE 32 LATERAL FLOW ASSAY COMPONENTS MARKET FOR FOOD SAFETY & ENVIRONMENTAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
7.5 DRUG DEVELOPMENT & QUALITY TESTING 97
7.5.1 INCREASING FOCUS ON PRODUCT SAFETY AND QUALITY ASSURANCE TO DRIVE MARKET GROWTH IN THE COMING YEARS 97
TABLE 33 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUG DEVELOPMENT & QUALITY TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 98
8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE 99
8.1 INTRODUCTION 100
TABLE 34 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 100
8.2 SANDWICH ASSAYS 100
8.2.1 SANDWICH ASSAYS PROVIDE HIGHER LEVELS OF ASSAY SENSITIVITY AND SPECIFICITY THAN OTHER ASSAY TECHNIQUES—A KEY FACTOR DRIVING GROWTH IN THIS MARKET SEGMENT 100
TABLE 35 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SANDWICH ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 101
8.3 COMPETITIVE ASSAYS 101
8.3.1 REDUCED SELECTIVITY AND SENSITIVITY OF COMPETITIVE ASSAYS IN RELATION TO SANDWICH ASSAYS COULD HAMPER MARKET GROWTH 101
TABLE 36 LATERAL FLOW ASSAY COMPONENTS MARKET FOR COMPETITIVE ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 102
8.4 MULTIPLEX DETECTION ASSAYS 102
8.4.1 INCREASING ADOPTION OF MULTI-ANALYTE ASSAYS AMONG CLINICIANS TO DRIVE MARKET GROWTH 102
TABLE 37 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MULTIPLEX DETECTION ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION) 103
9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER 104
9.1 INTRODUCTION 105
TABLE 38 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 105
9.2 MEDICAL DEVICE MANUFACTURING COMPANIES 105
9.2.1 INCREASING USE OF POC TESTS IS DRIVING THE ADOPTION OF LATERAL FLOW ASSAY COMPONENTS AMONG MEDICAL DEVICE MANUFACTURING COMPANIES 105
TABLE 39 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE MANUFACTURING COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 106
9.3 MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES 106
9.3.1 GROWING INCLINATION TOWARD FAST AND EARLY DIAGNOSIS, ESPECIALLY IN RELATION TO THE CURRENT COVID-19 SCENARIO, WILL DRIVE MARKET GROWTH 106
TABLE 40 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES, BY COUNTRY,
2020–2027 (USD MILLION) 107
 
10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION 108
10.1 INTRODUCTION 109
FIGURE 22 CHINA TO REGISTER THE HIGHEST GROWTH IN THE LATERAL FLOW ASSAY COMPONENTS MARKET DURING THE FORECAST PERIOD 109
TABLE 41 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION,
2020–2027 (USD MILLION) 110
10.2 NORTH AMERICA 110
TABLE 42 NORTH AMERICA: MACROECONOMIC INDICATORS 110
FIGURE 23 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 111
TABLE 43 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 44 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 45 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 112
TABLE 46 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 113
TABLE 47 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 113
TABLE 48 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 114
TABLE 49 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 114
TABLE 50 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 115
10.2.1 US 115
10.2.1.1 Increasing R&D investments and venture capital funding from both large and small firms towards the development of lateral flow assay diagnostics to drive market growth in the US 115
TABLE 51 US: MACROECONOMIC INDICATORS 116
TABLE 52 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 116
TABLE 53 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 116
TABLE 54 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 117
TABLE 55 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 117
TABLE 56 US: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 57 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 118
TABLE 58 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 119
10.2.2 CANADA 119
10.2.2.1 Lateral flow assay components market in Canada is estimated to grow at a relatively lower rate than the US 119
TABLE 59 CANADA: MACROECONOMIC INDICATORS 119
TABLE 60 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 120
TABLE 61 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 120
TABLE 62 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 120
TABLE 63 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 64 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 121
TABLE 65 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 122
TABLE 66 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 122
10.3 EUROPE 122
TABLE 67 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 68 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 123
TABLE 69 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 123
TABLE 70 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 124
TABLE 71 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 124
TABLE 72 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 73 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 125
TABLE 74 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 126
10.3.1 GERMANY 126
10.3.1.1 Growing demand for POC testing to drive the lateral flow assay components market in Germany 126
TABLE 75 GERMANY: MACROECONOMIC INDICATORS 126
TABLE 76 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 127
TABLE 77 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 127
TABLE 78 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 127
TABLE 79 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 128
TABLE 80 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 81 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 129
TABLE 82 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 129
10.3.2 FRANCE 129
10.3.2.1 High prevalence of age-related chronic diseases and infectious diseases to drive market growth in France 129
TABLE 83 FRANCE: MACROECONOMIC INDICATORS 130
TABLE 84 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 130
TABLE 85 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 130
TABLE 86 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 131
TABLE 87 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 131
TABLE 88 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 89 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 132
TABLE 90 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 133
10.3.3 UK 133
10.3.3.1 Severe impact of the second wave of COVID-19 in the first half of 2021 resulted in higher adoption of rapid COVID tests in the UK 133
TABLE 91 UK: MACROECONOMIC INDICATORS 134
TABLE 92 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 134
TABLE 93 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 134
TABLE 94 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 135
TABLE 95 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 135
TABLE 96 UK: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 97 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 136
TABLE 98 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 137
10.3.4 ITALY 137
10.3.4.1 Growing initiatives towards decentralization of medical services in Italy are contributing to the market growth in the country 137
TABLE 99 ITALY: MACROECONOMIC INDICATORS 137
TABLE 100 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 138
TABLE 101 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 138
TABLE 102 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 138
TABLE 103 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 139
TABLE 104 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 105 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 140
TABLE 106 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 140
10.3.5 SPAIN 140
10.3.5.1 Increasing focus of international organizations and domestic players on the development of POC products in the country to drive market growth 140
TABLE 107 SPAIN: MACROECONOMIC INDICATORS 141
TABLE 108 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 141
TABLE 109 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 142
TABLE 110 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 142
TABLE 111 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 142
TABLE 112 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 113 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 143
TABLE 114 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 144
10.3.6 REST OF EUROPE 144
TABLE 115 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 144
TABLE 116 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 145
TABLE 117 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 145
TABLE 118 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 145
TABLE 119 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 120 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 146
TABLE 121 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 147
10.4 ASIA PACIFIC 147
FIGURE 24 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 148
TABLE 122 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 149
TABLE 123 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 149
TABLE 124 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 149
TABLE 125 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 150
TABLE 126 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 150
TABLE 127 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 128 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 151
TABLE 129 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 152
10.4.1 CHINA 152
10.4.1.1 Higher exports of lateral flow assay components during the COVID-19 pandemic to drive market growth in the country 152
TABLE 130 CHINA: MACROECONOMIC INDICATORS 153
TABLE 131 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 153
TABLE 132 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 153
TABLE 133 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 154
TABLE 134 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 154
TABLE 135 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 155
TABLE 136 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 155
TABLE 137 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 156
10.4.2 JAPAN 156
10.4.2.1 Increasing prevalence of age-related illnesses driving the growth of the lateral flow assay components market in Japan 156
TABLE 138 JAPAN: MACROECONOMIC INDICATORS 157
TABLE 139 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 157
TABLE 140 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 157
TABLE 141 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 158
TABLE 142 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 158
TABLE 143 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 144 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 159
TABLE 145 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 160
10.4.3 INDIA 160
10.4.3.1 Increasing number of local manufacturers, growing healthcare concerns, and rising income levels to propel the growth of this market 160
TABLE 146 INDIA: MACROECONOMIC INDICATORS 160
TABLE 147 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 161
TABLE 148 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 161
TABLE 149 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 161
TABLE 150 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 162
TABLE 151 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 162
TABLE 152 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 163
TABLE 153 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 163
10.4.4 AUSTRALIA 164
10.4.4.1 Increasing prevalence of infectious diseases, especially influenza, to drive the growth of the lateral flow assay components market in Australia 164
TABLE 154 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 164
TABLE 155 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 164
TABLE 156 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 165
TABLE 157 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 165
TABLE 158 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 166
TABLE 159 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 166
TABLE 160 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 167
10.4.5 REST OF ASIA PACIFIC 167
TABLE 161 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 167
TABLE 162 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 168
TABLE 163 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 168
TABLE 164 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 168
TABLE 165 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 169
TABLE 166 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 169
TABLE 167 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 170
 
10.5 LATIN AMERICA 170
10.5.1 HIGH DEMAND FOR HIV POC DEVICES IN THE REGION TO SUPPORT THE GROWTH OF THE MARKET 170
TABLE 168 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 169 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 171
TABLE 170 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD
TYPE, 2020–2027 (USD MILLION) 171
TABLE 171 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 172
TABLE 172 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 172
TABLE 173 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 173
TABLE 174 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 173
10.6 MIDDLE EAST & AFRICA 173
10.6.1 SIGNIFICANT SUPPORT FROM GOVERNMENTS AND GLOBAL FIRMS TOWARDS EXPANDING HEALTHCARE SERVICES DRIVES THE ADOPTION OF LATERAL FLOW ASSAYS 173
TABLE 175 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 174
TABLE 176 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 174
TABLE 177 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 175
TABLE 178 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 175
TABLE 179 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 175
TABLE 180 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 181 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 176
TABLE 182 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 177
11 COMPETITIVE LANDSCAPE 178
11.1 OVERVIEW 178
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 178
FIGURE 25 OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
11.3 REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
FIGURE 26 REVENUE SHARE ANALYSIS FOR THE KEY PLAYERS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 180
11.4 MARKET SHARE ANALYSIS 180
FIGURE 27 LATERAL FLOW ASSAY COMPONENTS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 181
TABLE 183 LATERAL FLOW ASSAY COMPONENTS MARKET: DEGREE OF COMPETITION 182
11.5 R&D ASSESSMENT OF KEY PLAYERS 183
FIGURE 28 R&D EXPENDITURE: MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2018 VS. 2020 183
11.6 GEOGRAPHIC REVENUE ASSESSMENT OF KEY PLAYERS 183
FIGURE 29 GEOGRAPHIC REVENUE ASSESSMENT: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 184
11.7 COMPANY EVALUATION QUADRANT 184
11.7.1 STARS 184
11.7.2 PERVASIVE PLAYERS 184
11.7.3 EMERGING LEADERS 185
11.7.4 PARTICIPANTS 185
FIGURE 30 LATERAL FLOW ASSAY COMPONENTS MARKET: COMPANY EVALUATION MATRIX, 2021 185
11.8 COMPETITIVE BENCHMARKING 186
11.8.1 OVERALL COMPANY FOOTPRINT 186
TABLE 184 OVERALL COMPANY FOOTPRINT (17 COMPANIES) 186
TABLE 185 COMPANY FOOTPRINT: BY TYPE (17 COMPANIES) 187
TABLE 186 COMPANY FOOTPRINT: BY REGION (17 COMPANIES) 188
11.9 COMPETITIVE SCENARIO 188
11.9.1 DEALS 189
TABLE 187 DEALS, JANUARY 2019–FEBRUARY 2022 189
11.9.2 OTHER DEVELOPMENTS 189
TABLE 188 OTHER DEVELOPMENTS, JANUARY 2019–FEBRUARY 2022 189
12 COMPANY PROFILES 190
12.1 KEY PLAYERS 190
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 DANAHER CORPORATION (PALL CORPORATION AND CYTIVA LIFE SCIENCE) 190
TABLE 189 DANAHER CORPORATION: BUSINESS OVERVIEW 190
FIGURE 31 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 191
12.1.2 SARTORIUS STEDIM BIOTECH 195
TABLE 190 SARTORIUS STEDIM BIOTECH: BUSINESS OVERVIEW 195
12.1.3 MERCK KGAA 199
TABLE 191 MERCK KGAA: BUSINESS OVERVIEW 199
FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2020) 200
12.1.4 AHLSTROM-MUNKSJÖ 204
TABLE 192 AHLSTROM-MUNKSJÖ: BUSINESS OVERVIEW 204
FIGURE 34 AHLSTROM-MUNKSJÖ: COMPANY SNAPSHOT (2020) 205
12.1.5 ADVANCED MICRODEVICES PVT. LTD. 208
TABLE 193 ADVANCED MICRODEVICES PVT. LTD.: BUSINESS OVERVIEW 208
12.1.6 DCN DIAGNOSTICS 210
TABLE 194 DCN DIAGNOSTICS: BUSINESS OVERVIEW 210
12.2 OTHER PLAYERS 211
12.2.1 FORTIS LIFE SCIENCES 211
TABLE 195 FORTIS LIFE SCIENCES: BUSINESS OVERVIEW 211
12.2.2 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD 212
TABLE 196 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD.:
BUSINESS OVERVIEW 212
12.2.3 AXIVA SICHEM BIOTECH 214
TABLE 197 AXIVA SICHEM BIOTECH: BUSINESS OVERVIEW 214
12.2.4 NUPORE FILTRATION SYSTEM 216
TABLE 198 NUPORE FILTRATION SYSTEM: BUSINESS OVERVIEW 216
12.2.5 BALLYA BIO 217
TABLE 199 BALLYA BIO: BUSINESS OVERVIEW 217
12.2.6 RUNBIO BIOTECH CO. LTD. 219
TABLE 200 RUNBIO BIOTECH CO. LTD.: BUSINESS OVERVIEW 219
12.2.7 NEENAH GESSNER 220
TABLE 201 NEENAH GESSNER: BUSINESS OVERVIEW 220
12.2.8 MAXIM BIOMEDICAL 221
TABLE 202 MAXIM BIOMEDICAL: BUSINESS OVERVIEW 221
12.2.9 CYTODIAGNOSTICS 222
TABLE 203 CYTODIAGNOSTICS: BUSINESS OVERVIEW 222
12.2.10 SENOVA GMBH 223
TABLE 204 SENOVA GMBH: BUSINESS OVERVIEW 223
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 224
13.1 DISCUSSION GUIDE 224
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 229
13.3 AVAILABLE CUSTOMIZATIONS 231
13.4 RELATED REPORTS 231
13.5 AUTHOR DETAILS 232

US Healthcare Environmental Services Market by Type (Janitorial/Core-Cleaning, Infection Control & Prevention, Front-of-house cleaning & Brand Experie...

Publisher:        MarketsandMarkets

# of Pages:        126

Rating: 

1 User License $4,950

Publication Date:  March, 2022

Price:       $4,950 / User License




1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION & SCOPE 15
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 16
1.2.2 MARKET SEGMENTATION 16
FIGURE 1 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET SEGMENTATION 16
1.2.3 YEARS CONSIDERED FOR THE STUDY 17
1.3 CURRENCY 17
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 17
1.4 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH APPROACH 19
FIGURE 2 RESEARCH DESIGN 19
2.1.1 SECONDARY RESEARCH 20
2.1.1.1 Key data from secondary sources 21
2.1.2 PRIMARY RESEARCH 21
FIGURE 3 PRIMARY SOURCES 22
2.1.2.1 Key data from primary sources 23
2.1.2.2 Insights from primary experts 23
2.1.2.3 Breakdown of primary interviews 24
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE (SUPPLY & DEMAND SIDE) AND DESIGNATION 24
2.2 MARKET SIZE ESTIMATION 25
FIGURE 5 MARKET SIZE APPROACH – REVENUE SHARE ANALYSIS 25
FIGURE 6 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 26
FIGURE 7 DEMAND-SIDE APPROACH 28
2.3 DATA TRIANGULATION 29
FIGURE 8 DATA TRIANGULATION METHODOLOGY 29
2.4 MARKET RANKING ANALYSIS 30
2.5 ASSUMPTIONS FOR THE STUDY 30
2.6 LIMITATIONS 31
2.6.1 METHODOLOGY-RELATED LIMITATIONS 31
2.6.2 SCOPE-RELATED LIMITATIONS 31
2.7 RISK ASSESSMENT 31
TABLE 2 RISK ASSESSMENT: US HEALTHCARE ENVIRONMENTAL SERVICES MARKET 31
 
3 EXECUTIVE SUMMARY 32
FIGURE 9 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 32
FIGURE 10 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET,
BY FACILITY TYPE, 2021 VS. 2026 (USD MILLION) 33
4 PREMIUM INSIGHTS 34
4.1 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET OVERVIEW 34
FIGURE 11 STRINGENT REGULATORY GUIDELINES ON INFECTION CONTROL & PREVENTION METHODS IS A KEY FACTOR DRIVING THE MARKET GROWTH 34
4.2 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE AND FACILITY TYPE 35
FIGURE 12 JANITORIAL/CORE-CLEANING SERVICES ACCOUNTED FOR THE LARGEST SHARE OF THE US HEALTHCARE ENVIRONMENTAL SERVICES
MARKET IN 2020 35
4.3 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE (2021–2026) 36
FIGURE 13 ACUTE CARE FACILITIES TO DOMINATE THE US HEALTHCARE ENVIRONMENTAL SERVICES MARKET DURING THE FORECAST PERIOD 36
5 MARKET OVERVIEW 37
5.1 INTRODUCTION 37
5.2 MARKET DYNAMICS 37
TABLE 3 MARKET DYNAMICS: HEALTHCARE ENVIRONMENTAL SERVICES MARKET 37
5.2.1 MARKET DRIVERS 38
5.2.1.1 Increasing prevalence of Hospital-acquired infections (HAIs) 38
5.2.1.2 Rising number of hospital admissions and surgeries 39
TABLE 4 US: PERCENTAGE INCREASE IN THE NUMBER OF SURGERIES PERFORMED 39
FIGURE 14 TOTAL ADMISSIONS IN ALL US HOSPITALS 40
FIGURE 15 TOTAL NUMBER OF HOSPITALS IN THE US 40
5.2.1.3 Shortage of in-house expertise and the rising need to reduce healthcare costs 41
5.2.1.4 Increasing outsourcing of cleaning services 41
5.2.2 MARKET RESTRAINTS 41
5.2.2.1 Healthcare facilities with an in-house EVS department 41
5.2.3 MARKET OPPORTUNITIES 42
5.2.3.1 Sustained acquisitions among strategic & financial buyers 42
TABLE 5 COMPANY ACQUISITIONS 42
5.2.4 MARKET CHALLENGES 42
5.2.4.1 Noncompliance with cleaning standards by EVS providers 42
5.3 INDUSTRY TRENDS 43
5.3.1 EMERGENCE OF NEW SURFACE DISINFECTANTS &
GREEN CLEANING PRODUCTS 43
5.3.2 DISINFECTION ROBOTS 44
5.3.3 MONITORING TOOLS FOR CLEANING QUALITY ASSESSMENT 44
5.4 TECHNOLOGY ANALYSIS 45
TABLE 6 TECHNOLOGY INNOVATION IN THE HEALTHCARE ENVIRONMENTAL
SERVICES MARKET 45
5.5 PATENT ANALYSIS 45
5.5.1 PATENT PUBLICATION TRENDS FOR HEALTHCARE ENVIRONMENTAL SERVICES 46
FIGURE 16 PATENT PUBLICATION TRENDS (JANUARY 2011–DECEMBER 2021) 46
5.5.2 JURISDICTION AND TOP APPLICANT ANALYSIS 47
FIGURE 17 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR HEALTHCARE ENVIRONMENTAL SERVICES PATENTS (JANUARY 2011–JANUARY 2022) 47
FIGURE 18 TOP APPLICANT COUNTRIES/REGIONS FOR HEALTHCARE ENVIRONMENTAL SERVICES PATENTS (JANUARY 2011–JANUARY 2022) 48
TABLE 7 LIST OF PATENTS/PATENT APPLICATIONS IN THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET, 2020–2021 48
5.6 IMPACT OF COVID-19 ON THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET 50
6 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE 51
6.1 INTRODUCTION 52
TABLE 8 US: HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 52
6.2 JANITORIAL SERVICES/CORE-CLEANING SERVICES 52
6.2.1 MANDATORY REGULAR CLEANING AND DISINFECTION OF HEALTHCARE FACILITIES TO DRIVE THE MARKET GROWTH 52
6.3 INFECTION PREVENTION & CONTROL SERVICES 53
TABLE 9 US: INFECTION PREVENTION & CONTROL SERVICE MARKET, BY TYPE,
2019–2026 (USD MILLION) 53
6.3.1 SPECIALIZED CLEANING SERVICES 53
6.3.1.1 Rising adoption of specialized services to reduce HAIs to drive the market growth 53
6.3.2 INFECTION PREVENTION & CONTROL CONSULTATION SERVICES 53
6.3.2.1 The provision of customized environmental services specific
to a healthcare facility ensures market demand 53
6.4 ENHANCED CLEANING TECHNOLOGY 54
6.4.1 RISING DEMAND FOR ADVANCED CLEANING SOLUTIONS TO DRIVE THE SEGMENT GROWTH 54
TABLE 10 EXAMPLES OF COMPANIES PROVIDING TECHNOLOGY & INNOVATION IN HEALTHCARE EVS 54
6.5 FRONT-OF-HOUSE CLEANING AND BRAND EXPERIENCE 56
6.5.1 RISING AWARENESS TOWARDS A CLEAN AND SAFE ENVIRONMENT DURING PANDEMICS TO SUSTAIN THE MARKET GROWTH 56
6.6 OTHER SERVICES 56
 
7 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE 57
7.1 INTRODUCTION 58
FIGURE 19 STATES WITH THE HIGHEST NUMBER OF COVID-19 ADMISSIONS
(FEBRUARY 2022) 58
TABLE 11 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE, 2019–2026 (USD MILLION) 59
7.2 ACUTE-CARE FACILITIES 59
TABLE 12 US: HEALTHCARE ENVIRONMENTAL SERVICES FOR ACUTE-CARE SETTINGS, BY TYPE 2019–2026 (USD MILLION) 59
7.2.1 ACUTE HOSPITALS 60
7.2.1.1 Increasing hospital admissions due to COVID-19 and the rising prevalence of HAIs propel the market growth 60
FIGURE 20 NUMBER OF HAIS REPORTED BY GENERAL ACUTE CARE HOSPITALS
IN THE US (2020) 60
FIGURE 21 HAIS REPORTED BY GENERAL ACUTE CARE HOSPITALS IN THE US (2020) 61
FIGURE 22 HAIS REPORTED BY CRITICAL ACCESS HOSPITALS (CAHS) IN THE US (2018) 61
7.2.2 MILITARY TREATMENT FACILITY 61
7.2.2.1 The increasing number of military ambulatory health services & funding to drive the market growth 61
FIGURE 23 MILITARY HEALTH SYSTEMS FACILITIES IN THE US (2021) 62
7.2.3 CHILDREN’S HOSPITALS 62
7.2.3.1 Rising cases of COVID-19 and infection-related mortality rates among children drive the market growth 62
7.2.4 AMBULATORY SURGERY CENTERS (ASCS) 63
7.2.4.1 ASCs save time and reduce the risk of HAIS; key factor driving the market growth 63
FIGURE 24 US SURGERY CASES BY SETTING: ASC VS. HOPD (2005-2020) 64
7.2.5 ACADEMIC MEDICAL CENTERS (AMCS) 64
7.2.5.1 Healthcare capacity expansion during COVID-19 drives the adoption of healthcare environmental services in AMCs 64
7.3 POST-ACUTE CARE FACILITIES 64
TABLE 13 US: HEALTHCARE ENVIRONMENTAL SERVICES FOR POST-ACUTE CARE SETTINGS, BY TYPE 2019–2026 (USD MILLION) 65
7.3.1 LONG-TERM ACUTE HOSPITALS (LTACH) 65
7.3.1.1 Increasing risk of infection due to prolonged hospital stays to drive the market growth 65
7.3.2 SKILLED NURSING FACILITIES (SNF) 66
7.3.2.1 Increasing admissions of elderly people in skilled nursing facilities to drive the market growth 66
7.3.3 OTHER POST-ACUTE CARE FACILITIES 66
7.4 NON-ACUTE CARE FACILITIES 67
TABLE 14 US: ENVIRONMENTAL SERVICES MARKET FOR NON-ACUTE CARE SETTINGS, BY TYPE, 2019–2026 (USD MILLION) 67
7.4.1 PHYSICIAN’S OFFICES AND CLINICS 67
7.4.1.1 High patient traffic leads to continuous cleaning & maintenance to drive the market growth 67
7.4.2 OTHER NON-ACUTE CARE FACILITIES 68
FIGURE 25 DISTRIBUTION OF INDUSTRY MEDICAL AND HEALTH R&D INVESTMENTS,
BY SEGMENT (2020) 68
8 COMPETITIVE LANDSCAPE 70
8.1 OVERVIEW 70
8.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 70
8.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET 71
8.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 72
8.4 MARKET RANKING ANALYSIS 73
FIGURE 27 US HEALTHCARE ENVIRONMENTAL SERVICE MARKET RANKING,
BY KEY PLAYER, 2020 73
8.5 COMPETITIVE BENCHMARKING 75
TABLE 15 FOOTPRINT OF COMPANIES IN THE HEALTHCARE ENVIRONMENTAL
SERVICES MARKET 75
TABLE 16 SERVICE FOOTPRINT OF COMPANIES 76
TABLE 17 END-USER FOOTPRINT OF COMPANIES 77
8.6 COMPETITIVE LEADERSHIP MAPPING 77
8.6.1 STARS 78
8.6.2 EMERGING LEADERS 78
8.6.3 PERVASIVE PLAYERS 78
8.6.4 PARTICIPANTS 78
FIGURE 28 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET:
COMPETITIVE LEADERSHIP MAPPING (2021) 79
8.7 COMPETITIVE SCENARIO 80
8.7.1 SERVICE APPROVALS/ENHANCEMENTS 80
8.7.2 DEALS 81
TABLE 19 DEALS, 2018–2022 81
8.7.3 OTHER DEVELOPMENTS 82
9 COMPANY PROFILES 83
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
9.1 SODEXO GLOBAL 83
TABLE 21 SODEXO GLOBAL: BUSINESS OVERVIEW 83
FIGURE 29 SODEXO GLOBAL: COMPANY SNAPSHOT (2021) 84
9.2 COMPASS GROUP (CROTHALL HEALTHCARE (US)) 87
TABLE 22 COMPASS GROUP: BUSINESS OVERVIEW 87
FIGURE 30 COMPASS GROUP: COMPANY SNAPSHOT (2021) 88
 
9.3 ARAMARK CORPORATION 90
TABLE 23 ARAMARK CORPORATION: BUSINESS OVERVIEW 90
FIGURE 31 ARAMARK CORPORATION: COMPANY SNAPSHOT (2021) 91
9.4 HOSPITAL HOUSEKEEPING SYSTEMS (HHS) (US) 94
TABLE 24 HOSPITAL HOUSEKEEPING SYSTEMS (HHS): BUSINESS OVERVIEW 94
9.5 HEALTHCARE SERVICES GROUP, INC. 97
TABLE 25 HEALTHCARE SERVICES GROUP, INC.: BUSINESS OVERVIEW 97
FIGURE 32 HEALTHCARE SERVICES GROUP: COMPANY SNAPSHOT (2020) 98
9.6 ABM INDUSTRIES INCORPORATED 100
TABLE 26 ABM INDUSTRIES INCORPORATED: BUSINESS OVERVIEW 100
FIGURE 33 ABM INDUSTRIES INCORPORATED: COMPANY SNAPSHOT (2020) 101
9.7 OCTOCLEAN 103
TABLE 27 OCTOCLEAN: BUSINESS OVERVIEW 103
9.8 SERVICEMASTER CLEAN (SERVICEMASTER TBS) 105
TABLE 28 SERVICEMASTER CLEAN.: BUSINESS OVERVIEW 105
9.9 CORVUS JANITORIAL SYSTEMS 107
TABLE 29 CORVUS JANITORIAL SYSTEMS: BUSINESS OVERVIEW 107
9.10 BRAVO! BUILDING SERVICES 109
TABLE 30 BRAVO! BUILDING SERVICES: BUSINESS OVERVIEW 109
9.11 POWERLINK ENVIRONMENTAL SERVICES, LLC 111
TABLE 31 POWERLINK ENVIRONMENTAL SERVICES, LLC: BUSINESS OVERVIEW 111
9.12 JANI-KING INTERNATIONAL, INC. 112
TABLE 32 JANI- KING INTERNATIONAL, INC: BUSINESS OVERVIEW 112
9.13 AVI FOOD SYSTEMS(US) 114
TABLE 33 AVI FOOD SYTEMS, INC.: BUSINESS OVERVIEW 114
9.14 SERVICON 115
TABLE 34 SERVICON: BUSINESS OVERVIEW 115
9.15 XANITOS, INC. 117
TABLE 35 XANITOS, INC.: BUSINESS OVERVIEW 117
9.16 STATHAKIS 119
TABLE 36 STATHAKIS: BUSINESS OVERVIEW 119
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
10 APPENDIX 120
10.1 INSIGHTS FROM INDUSTRY EXPERTS 120
10.2 DISCUSSION GUIDE 121
10.3 KNOWLEDGESTORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL 124
10.4 AVAILABLE CUSTOMIZATIONS 126
10.5 RELATED REPORTS 126
10.6 AUTHOR DETAILS 127